🔍

PFIZER - Pfizer

📊 NSE: PFIZER 🏢 Pharmaceuticals - Multinational 📅 Last Updated: 12/14/2025 10:58

📢 Recent Corporate Announcements

Pfizer Ltd Q3 Net Profit Rises 11% YoY to ‡141.8 Cr; Revenue Up 20%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 09 Feb 2026, 07:29 PM

Pfizer Limited reported a strong 20% year-on-year growth in revenue from operations, reaching ‡645.03 crore for the quarter ended December 31, 2025. Despite an exceptional charge of ‡58.20 crore related to workforce restructuring and new labor code provisions, net profit grew by 11% to ‡141.84 crore. The company entered a strategic agreement with Cipla for the distribution of four key brands, leading to a one-time separation cost of ‡39.58 crore. Overall, the operational performance remains robust with a significant 19.7% improvement in nine-month profitability compared to the previous year.

Revenue from operations grew 19.9% YoY to ‡645.03 crore from ‡537.99 crore in the previous year.
Net profit increased 11.2% YoY to ‡141.84 crore, overcoming a ‡58.20 crore exceptional charge.
Exceptional items include ‡39.58 crore for personnel separation following a distribution deal with Cipla for four brands.
A provision of ‡18.62 crore was recorded to account for the impact of the Government's New Labour Codes.
Nine-month net profit stands at ‡522.61 crore, up significantly from ‡436.66 crore in the corresponding period last year.

💡 Investors should focus on the strong double-digit revenue growth and the strategic partnership with Cipla which aims to optimize distribution for key brands. The one-time exceptional costs are non-recurring, indicating healthy underlying operational margins.

Pfizer Limited Announces Senior Management Changes Effective February 1, 2026

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 20 Jan 2026, 09:41 AM

Pfizer Limited has announced a restructuring of its senior management team effective February 1, 2026. Mr. Nilesh Pendse, formerly of BCG and Novartis, has been appointed as the Category Lead for Vaccines. Concurrently, Mr. Manikantan Seshadrinathan will transition to a different role within the Pfizer Group, and Mr. Prashant Mahalingam will take on additional responsibilities for the Hospitals business. These changes represent a strategic realignment of leadership across key therapeutic categories.

Mr. Nilesh Pendse appointed as Category Lead – Vaccines effective February 1, 2026
Mr. Manikantan Seshadrinathan to transition to another Pfizer Group role effective January 31, 2026
Mr. Prashant Mahalingam redesignated as Category Lead – Internal Medicine & Hospitals
New appointee Nilesh Pendse brings experience from BCG, EY, Accenture, and Novartis

💡 These management changes are part of routine organizational restructuring and do not require immediate action. Investors should monitor the performance of the Vaccines and Hospitals segments under the new leadership.

Pfizer Limited Files Routine SEBI Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 09 Jan 2026, 11:44 AM

Pfizer Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations for the period ending December 31, 2025. The certificate, issued by KFin Technologies Limited, confirms that all share dematerialization requests were processed and confirmed to depositories within the mandated 30-day timeframe. It also verifies that physical certificates were mutilated and cancelled after due verification. This is a standard procedural filing required for all listed companies in India to ensure the integrity of the shareholding records.

Compliance certificate submitted for the quarter ended December 31, 2025
Issued by Registrar and Share Transfer Agent, KFin Technologies Limited
Confirms dematerialization requests were processed and updated in the register within 30 days
Verification that security certificates were mutilated and cancelled after processing

💡 This is a routine administrative filing with no impact on the company's fundamentals or stock price; no action is required from investors.

Pfizer Limited Announces Trading Window Closure from December 31, 2025

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 29 Dec 2025, 04:06 PM

Pfizer Limited has informed the stock exchanges that its trading window for dealing in company shares will be closed starting from the close of business on December 31, 2025. This action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the declaration of unaudited financial results for the quarter ending December 31, 2025. The window will remain closed until 48 hours after the financial results are officially made public. This is a standard regulatory procedure for all listed Indian companies to prevent insider trading during the earnings preparation period.

Trading window closure begins from the close of business on Wednesday, December 31, 2025.
The closure is linked to the upcoming announcement of unaudited financial results for the quarter ending December 31, 2025.
The window will reopen 48 hours after the financial results are disclosed to the public.
Compliance is maintained under the SEBI (Prohibition of Insider Trading) Regulations, 2015.

💡 No action is required as this is a routine regulatory filing. Investors should monitor the company's future announcements for the specific date of the Q3 financial results release.

Pfizer Limited Receives GST Demand and Penalty of Rs 8.79 Crore from West Bengal Authorities

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 28 Dec 2025, 12:42 PM

Pfizer Limited has received a GST demand order from the Additional Commissioner of GST & CX, Kolkata, West Bengal. The total demand amounts to Rs 8.79 crore, which includes a tax demand of Rs 4.40 crore and an equivalent penalty of Rs 4.40 crore plus interest. The order pertains to the period from FY 2018-19 to FY 2022-23 regarding alleged incorrect availment of Input Tax Credit. The company has stated that the demand is not maintainable and intends to file an appeal against the order.

Total demand of Rs 8,79,11,396 includes tax and penalty of Rs 4,39,55,698 each.
The order covers a five-year period from Financial Year 2018-19 to 2022-23.
Allegation involves incorrect availment of Input Tax Credit (ITC) discovered during a GST audit.
Pfizer Limited confirms that the order has no material impact on its financials or operations.
The company is in the process of preferring an appeal against the said order.

💡 Investors need not worry as the demand amount is immaterial relative to Pfizer's balance sheet and operations. Monitor the outcome of the appeal in future disclosures.

Pfizer Ltd Receives GST Demand and Penalty Totaling Rs 1.27 Crore

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 24 Dec 2025, 06:19 PM

Pfizer Limited has received a GST demand order from the Joint Commissioner, Lucknow, for the financial year 2021-22. The total demand, including a penalty of Rs 11.53 lakh, amounts to approximately Rs 1.27 crore plus applicable interest. The demand stems from the denial of Input Tax Credit (ITC) claimed by the company during the audit period. Pfizer has stated that the demand is not maintainable and intends to file an appeal, asserting that there is no material impact on its financial operations.

Total GST demand of Rs 1,26,87,141 including tax and penalty components.
Specific tax demand of Rs 1,15,33,764 and a penalty of Rs 11,53,377 for FY 2021-22.
The order was issued by the Office of the Joint Commissioner, Corporate Circle, Lucknow, Uttar Pradesh.
The demand is based on the denial of Input Tax Credit (ITC) due to alleged lack of clear documentation.
Pfizer is in the process of preferring an appeal and expects no material impact on financials.

💡 This is a routine tax dispute with a negligible financial impact relative to the company's size. No immediate action is required as the company is contesting the demand through legal channels.

Pfizer Ltd Senior Management Change: Category Lead – Vaccines Aditi Mehta Resigns

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 23 Dec 2025, 01:51 PM

Pfizer Limited has announced the resignation of Ms. Aditi Mehta, who currently serves as the Category Lead – Vaccines. Her resignation is set to become effective from the close of business on January 2, 2026. Ms. Mehta is leaving the organization to pursue professional opportunities outside of Pfizer Limited. Following her departure, she will cease to be a member of the Senior Management Personnel as per regulatory definitions.

Ms. Aditi Mehta, Category Lead – Vaccines, has resigned from Pfizer Limited.
The resignation is effective from the close of business hours on January 2, 2026.
The departure is intended to allow the executive to pursue opportunities outside the company.
The company has complied with SEBI Regulation 30 regarding the disclosure of senior management changes.

💡 This is a routine management transition at the category level and is unlikely to impact the stock price. Investors should monitor for the appointment of a successor to ensure business continuity in the vaccine segment.

Pfizer Partners with Cipla for Exclusive Marketing of 4 Key Brands for 5 Years

🔵 WATCH ⭐ 8/10

EXPANSION 📅 19 Dec 2025, 11:40 AM

Pfizer Limited has entered into a strategic 5-year exclusive agreement with Cipla Limited for the marketing and distribution of four key brands: Corex Dx, Corex LS, Dolonex, and Neksium in India. Under this arrangement, Pfizer will continue to manufacture and supply these medicines while leveraging Cipla's extensive distribution network to enhance market reach. Notably, the company announced this shift will result in a reduction of its own field force, with the associated financial impact to be disclosed in upcoming quarterly results. This move indicates a strategic pivot towards a leaner operating model for these specific legacy brands.

Exclusive 5-year marketing and distribution agreement signed with Cipla Limited for four major brands.
Brands included in the deal are Corex Dx, Corex LS, Dolonex, and Neksium.
Pfizer Limited will retain all manufacturing and supply responsibilities for the products.
The agreement will lead to a reduction in Pfizer's field force, with severance or transition costs to be reported later.
No upfront consideration was exchanged; commercial terms are based on ongoing supply and marketing arrangements.

💡 Investors should monitor the next financial statement for one-time restructuring costs related to the field force reduction. Long-term value depends on whether Cipla's distribution scale can drive enough volume growth to offset the change in margin structure.

View All PFIZER Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The company operates in a single segment, 'Pharmaceuticals'. In Q1 2020-21, Internal Medicine grew 13%, while Vaccines declined 23% and Hospital revenue fell 41%. Overall revenue for Q1 2020-21 was INR 515 Cr, a decline of 5.3% YoY from INR 544 Cr.

Geographic Revenue Split

Not disclosed in available documents, though the company operates primarily in India with service revenue of INR 10 Cr from Pfizer Inc. affiliates.

Profitability Margins

For FY 2025, Net Profit Margin was 33.65% (up from 25.14% in FY 2024) and Operating Profit Margin was 29.78% (up from 26.13% YoY). Q1 2020-21 Gross Margin was 65% (INR 327 Cr) vs 64% YoY.

EBITDA Margin

Operating Profit Margin for FY 2025 stood at 29.78%, representing a 13.9% YoY improvement from 26.13%. Q1 2020-21 profit from operations was INR 159 Cr, a 13% growth YoY.

Capital Expenditure

Not explicitly disclosed, but the company realized a net gain of INR 172.81 Cr from the sale of leasehold rights and buildings at Thane to Zoetis in FY 2025.

Credit Rating & Borrowing

Not disclosed in available documents; however, the company reported N.A. for debt-equity and interest coverage ratios, indicating a debt-free status.

⚙️ Operational Drivers

Raw Materials

Not disclosed in available documents, though COGS (Cost of Materials Consumed and Purchases of Stock-in-Trade) represents approximately 35% of sales based on a 65% gross margin.

Key Suppliers

Pfizer Inc. affiliates provide services and likely product supply to Pfizer Limited.

Raw Material Costs

Cost of materials and stock-in-trade purchases represent approximately 35% of revenue (INR 176 Cr in Q1 2020-21). Procurement is influenced by product mix and global affiliate sourcing.

Logistics & Distribution

Freight and forwarding charges decreased in Q1 2020-21 due to lower sales volumes and movement restrictions.

📈 Strategic Growth

Expected Growth Rate

0.8-2%

Growth Strategy

Growth is driven by a three-pronged strategy: a specialty focus leveraging science, customized go-to-market solutions (hybrid FTE/contract models), and maximizing the share of the global product portfolio, which increased from 36.3% in 2016 to 48.6% in 2020.

Products & Services

Pediatric vaccines, Internal Medicine drugs (legacy brands), Oncology treatments, and Hospital-based specialty therapies.

Brand Portfolio

Upjohn (divesting), Consumer Healthcare (divesting), and Pfizer Global Portfolio products.

New Products/Services

The company is considering several new products from its patented global basket to drive future revenue contribution.

Market Expansion

Expansion of distribution and coverage through a hybrid sales model and increased 'feet on the ground' in targeted territories.

Market Share & Ranking

Pfizer Limited reported 3.9% growth (MAT June 2020) compared to MNC industry growth of 3.7%.

Strategic Alliances

Divestment of Thane assets to Zoetis for INR 172.81 Cr and ongoing service agreements with Pfizer Inc. affiliates.

🌍 External Factors

Industry Trends

The industry is shifting toward chronic therapies and specialty portfolios; recovery was expected in 2021 following a 4.9% industry contraction in early 2020.

Competitive Landscape

MNCs grew at 3.7% vs Indian companies at 7.7% (MAT June 2020), indicating higher competition from local generic players.

Competitive Moat

Durable moat through a 70-year brand presence in India and a growing share of global patented products (48.6% of sales), which are harder to replicate than generics.